Comparing Mexartan and Calcium Channel Blockers for Treating High Blood Pressure
Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study
This study is testing whether Mexartan or Calcium Channel Blockers work better for treating high blood pressure in adults who have just been diagnosed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1215 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hasten Biopharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05947448 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the efficacy and safety of Mexartan Potassium tablets and Calcium Channel Blockers in treating adults with essential hypertension across 80 centers in China. A total of 1215 patients with newly diagnosed hypertension will be enrolled and divided into three treatment groups: Mexartan monotherapy, Calcium Channel Blocker monotherapy, and a combination of both. Patients will be monitored over six months with visits at baseline, one month, three months, and six months to assess key health indicators as determined by their doctors.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been newly diagnosed with essential hypertension and have not received antihypertensive treatment for at least three months prior to enrollment.
Not a fit: Patients who have been treated with antihypertensive drugs for other indications within the last three months or those with a life expectancy of less than one year may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the most effective treatment options for managing essential hypertension in the Chinese population.
How similar studies have performed: While this approach is observational, similar studies have shown promise in evaluating treatment efficacy for hypertension, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years old (one year old); 2. Patients diagnosed with essential hypertension; 3. Did not receive any antihypertensive drug treatment for at least 3 months before enrollment; 4. Eligible to use 80 mg once-daily AZL-M at baseline or CCB (amlodipine besylate tablets or nifedipine controlled-release tablets) or CCB (besylate Amlodipine tablets or nifedipine controlled-release tablets) + AZL-M 80 mg once-daily combination therapy; Volunteer to participate in this study, understand and sign the written informed consent. Exclusion Criteria: 1. Used antihypertensive drugs for indications other than hypertension within 3 months before enrollment; 2. Has a history of alcoholism, drug abuse or illegal drug use; 3. Pregnant, breastfeeding women, and those who plan to become pregnant in the near future; 4. Life expectancy is less than one year; Participating in other clinical trials.
Where this trial is running
Shanghai, Shanghai
- Junbo Ge — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Jun Bo Ge, academician
- Email: ge.junbo@zs-hospital.sh.cn
- Phone: +86 13901977506
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.